Armata Pharmaceuticals’ (ARMP) Buy Rating Reaffirmed at HC Wainwright

Armata Pharmaceuticals (NYSEAMERICAN:ARMP)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $7.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 258.97% from the stock’s current price.

Armata Pharmaceuticals Stock Performance

Shares of ARMP opened at $1.95 on Thursday. The company has a market cap of $70.55 million, a PE ratio of -1.19 and a beta of 0.78. Armata Pharmaceuticals has a 1 year low of $1.89 and a 1 year high of $4.48.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.